chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. No pertinent medical history or drug reactions/allergies were provided. On 03-APR-2015, the patient was vaccinated with ZOSTAVAX 19400 PFU, intramuscularly (dose and lot number not provided). No co-suspect or concomitant therapies were provided. The pharmacist reported that on 03-APR-2015 the patient was inadvertently administered ZOSTAVAX intramuscularly rather than subcutaneously. The pharmacist also reported that the patient was anxious because ZOSTAVAX was administered by the wrong route. At the time of the report, the outcome of the events was unknown. Additional information has been requested.
On 9/21/05 patient developed a dry cough.  On 9/24/05 in the afternoon, he developed a maculopapular rash on his face with fever of 103.  Rash worsened and by the next morning had spread to torso, fever 101.7, and he became lethargic.  By afernoon, rash had spread down back and onto extremities, and he developed diarrhea and red rimmed eyes.
Patient resides in nursing home - was seen at outside facility and tested positive for COVID on 9/20-9/22 (outside records unclear). Admitted to this institution on 10/1, brought in by EMS from nursing facility due to being unresponsive but breathing.  Pt unresponsive to Narcan; intubated in ED and started on IV pressors and fluids for hypotension.  Repeat COVID testing +; Chest Xray showed opacities at the bases - concern for residual COVID vs bacterial secondary PNA; empirically started on cefepime/vanc.  Admitted for sepsis - found to have E coli bacteremia and UTI - was on cefepime. Pt initially improved and was extubated but then declined again; family made decision to pursue palliative care.   Patient was COVID+ on this admission although her symptoms appear to be from the sepsis/UTI. Previous information on her COVID infection from 9/22 is unavailable to this reporter.
swelling of fingers 2nd hand (no pain) 3 days p/shot; bottom of feet itching; some swellings;
In PM of day of vaccination (Wed) dev hives, flushing and warmth on face, neck and chest. Confluent on face, blotchy on chest. The following day flu like sx, chills, some swelling of arm, that pm dev fever 103 and arthralgia SI joints, hands, feet and ankles. Fri seen tx with Hydroxyzine, Tylenol, ranitidine, and Allegra. 18 may pain persisted given prednisone. Slight relief. Pain persists and currently(Aug 20) given another course of Steroids and undergoing Rheum eval. Diagnosed with seroneg RA.  2 yrs later, joint pain remains, controlled with Humara, and steroids for flares.   Symptoms: FEVER, UNSPECIFIED(R509), PAIN IN UNSPECIFIED JOINT(M2550), URTICARIA, UNSPECIFIED(L509).
Site where patient receive injection was sore. Patient ignored it for the first couple of days. Now patient is Experiencing pain in both of her elbows.
Unable to swallow food and liquids beginning Saturday 7pm 08 May 2021.
Pt stated she developed swollen/red eyes, stiff neck at 8 PM on Wed 10/1/14, then developed body aches, soreness in upper chest the following day.
Temporary paralysis in left arm for 3 weeks. Arm was completely immobile and was dominant hand. I could write because I could bend my wrist some, but it was very difficult. I had to physically lift my arm with my right arm. My skin had sensation but my arm would not move. I still have phamtom pains to this day at the injection site and sometimes my arm randomly goves out on occassion no matter if I am using it or not. No treatment was given after symptoms were explained, we were told to just wait it out.
Could not raise it above shoulder, when turning steering wheel pain with up and over motion, could not lift anything; patient's left arm was very sore, achy; Bruise on injection site; This is a spontaneous report from a contactable other hcp.  A 49-years-old female patient started to receive bnt162b2 (BNT162B2) , via an unspecified route of administration, lot number: EH9899, from 23Dec2020 11:00 at a SINGLE DOSE for COVID-19 immunization.  Medical history included obesity, hyperthyroid and vit d deficiency. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient hasn't been tested for COVID-19. Patient was not pregnant. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Concomitant medication included topiramate (TOPAMAX), bupropion, darifenacin (ENABLEX) and levothyroxine. On 23Dec2020 15:00, the patient's left arm was very sore, achy, could not raise it above shoulder, when turning steering wheel pain with up and over motion, could not lift anything. Pain was described as worse than flu shot which lasted 24 hours. She also had bruise on injection site that lasted two weeks. Outcome of events was recovered. No treatment was received/required due to events.  No follow-up attempts are possible. Information about lot/batch number cannot be obtained. No further information is expected.
My son received 0.5 ml of the DTaP shot from a presealed syringe in his right thigh on 1/28/2020. Immediately after shot the injection site became red, swollen, and a hard lump formed under the injection site. On the night of the shot and the night after the shot, he was fussy and did not sleep well. On 1/30/2020 around 11am, he broke out in a hive-like rash covering his arms, legs, and lower face. He was brought to the pediatrician and upon arrival around 1:30pm, the rash had subsided. Doctor recommended Benadryl. Around 4pm on 1/30/2020, the rash reappeared and was much more severe. The rash was very red with hive-like welts covering his arms, legs, lower face, and belly. This appearance lasted about 45 minutes. One dose of Benadryl was given around 4:15pm. At around 7:15pm, it appeared again, but not as severe. This time only on his chin, belly, and a little on the arms. Overnight on 1/30/2020, he developed a stuffy nose. On 1/31/2020 at 8:45am, rash appeared on the same leg as the injection site. Around 9:45am, the rash spread to his back and arm. Around 10am, it spread to more of his back. At around 11:30am, it had mostly cleared up again. At around 12pm, it appeared again very severely. The rash now covered his whole belly and spread to his face and leg of the injection site at around 1pm, this time lasting until 2:30pm.  The rest of the day on 1/31/2020 the rash appeared smaller and lighter throughout the rest of the day. Rash still present at the time of this report.
This is a spontaneous report from a contactable consumer. A 47-year-old female patient received unknown dose number of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine, solution for injection, batch/lot# not reported), via an unspecified route of administration, on an unspecified date, single dose, for COVID-19 immunisation. The patient's medical history included non-smoker. Concomitant medications not reported. On unspecified date, patient experienced 100.8 fever, chills and can't hard move the arm she got the shot in; with outcome of unknown. The patient is  perfectly healthy. The reporter asked about concomitant use with Viagra (sildenafil citrate) and about alcohol consumption. Information about lot/batch number cannot be obtained. No further information expected.
according to ER, some kind of infection inflamed the nerves in my back and chest causing severe nerve pain.  They were not able to identify the nature of the infection or the cause.  They said it was similar to shingles - but not shingles. It has been 2 weeks and while the pain has decreased due to the METHYLPREDNISOLONE - it has not subsided completely.  ER doctors said it may take months. I can't say that this was due to the vaccine - but I have never had an issue like this before so I thought I would report it in case there are others reporting something similar
4/7/21 12:25 PM B/P 150/98, P 97, 12:40 PM Pulse 78.  Chief Complaint syncope and cold sweats, history of syncopal events associated with needles, patient briefly lost consciousness and fell to the ground from standing without hitting his head, regained consciousness and rested.
Information has been received from a registered nurse concerning a male patient age 7 to 10 years old who was vaccinated SC in the arm with first and second 0.5mL dose of varicella virus vaccine live (Oka/Merck) (Lot number 657457/0601U). It was reported that 24 hours post the booster dose of varicella virus vaccine live (Oka/Merck) he developed a large, red, hard and swollen area at the injection site. Unspecified medical attention was sought.  No treatment was provided. No product quality complaint was involved. This is one of several reports from the same source. Additional information has been requested.
This spontaneous report as received from a healthcare worker and a registered nurse refers to a patient of unknown age. The patient received expired GARDASIL (lot# 1130X exp date 13-MAR-2011, dose and route unspecified) on 21-SEP-2012. No adverse event reported. At the time of reporting, the outcome was unknown. This is one of several reports received from the same source. Additional information has been requested.
This spontaneous report as received from a nurse refers to an unspecified number of patients of unknown age and gender. The patient's medical history and concurrent conditions were not reported. On an unknown date, the patients were vaccinated with an improperly stored PNEUMOVAX 23, (dose and route were not reported), lot # K007826 expiration date 03-FEB-2016 and other lot # was reported as K016153 expiration date 24-SEP-2016. No adverse effects were reported. The patient's concomitant therapies were not reported. This is one of two reports from the same source. Additional information has been requested.
Patient called us on 10/14/22 saying that she woke up this morning and found a large rash covering her chest, she is unsure how long that rash was there for. Patient denies difficulty breathing, swelling, itching, or pain. Advised patient to call and follow up with pcp.
tested positive for covid/Antigen covid test; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (tested positive for covid/Antigen covid test) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 14-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Jun-2021, the patient experienced COVID-19 (tested positive for covid/Antigen covid test). At the time of the report, COVID-19 (tested positive for covid/Antigen covid test) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 02-Jun-2021, SARS-CoV-2 test: positive (Positive) SARS-CoV-2 test positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported.   Treatment information was not provided.
started feeling weird; numbness on his legs, entirely/ numbness on intimate parts/ numbness on anus; he could not walk; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (started feeling weird), HYPOAESTHESIA (numbness on his legs, entirely/ numbness on intimate parts/ numbness on anus) and GAIT DISTURBANCE (he could not walk) in a 56-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003C21A) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension and Cholesterol. Concomitant products included ASPIRIN [ACETYLSALICYLIC ACID] for an unknown indication.    On 27-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced FEELING ABNORMAL (started feeling weird), HYPOAESTHESIA (numbness on his legs, entirely/ numbness on intimate parts/ numbness on anus) and GAIT DISTURBANCE (he could not walk). The patient was treated with GABAPENTIN at a dose of 300 mg twice a day. At the time of the report, FEELING ABNORMAL (started feeling weird), HYPOAESTHESIA (numbness on his legs, entirely/ numbness on intimate parts/ numbness on anus) and GAIT DISTURBANCE (he could not walk) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications included high blood pressure medication, cholesterol medication. Patient had an MRI done from his cervical spine down and his Neurosurgeon told him that he had something (caller mentioned doctor used a term he could not recall) related to a virus On 04 Jun 2021 it was the last day he could go to work and then he went to the ER and had several studies done, it's been 6 weeks since he cannot go to work.   This case was linked to MOD-2021-256809 (Patient Link).
12FEB93 blotchy red area on lt thigh @ site of inject; covers over one half of thigh warm to touch; no fever; does not appear to be in distress;
8/20/21 PMH PAD, BPH, Arthritis, Aortic atherosclerosis, Urinary retention, chronic low back pain, sepsis d/t UTI. Pt admitted for fall at home while on blood thinners.
Symptoms of slight fever that passed for a few days; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Symptoms of slight fever that passed for a few days) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PYREXIA (Symptoms of slight fever that passed for a few days). At the time of the report, PYREXIA (Symptoms of slight fever that passed for a few days) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant product use was provided by the reporter. No treatment medication was provided.
never got the second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose in September 2019).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: never got the second dose). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 26-JUN-2023 The reporter asked if the patient had to restart the series. The reported did not provide patient information nor vaccine data (lot number, expiry date). Till the time of reporting, the patient did not receive the 2nd dose of Shingrix, which led to incomplete course of vaccination.
Sore upper arm beginning day after administration, becoming increasingly painful over the last 4 weeks. Hurts to lift arm.
Patient reports getting a stingy boil that's 3/4ths of an inch that appeared on the same arm as the vaccinated arm on 4/17/21, it popped today on 4/19/21 and a clear substance came out.
Information has been received from a registered nurse concerning a 21 year old Caucasian female patient who on 01/13/00 was vaccinated with a 1st dose of Hepatitis B vaccine recombinant. Immediately following vaccination, the patient became pale, dizzy, diaphoretic and experienced a hot flush. Fifthteen minutes later the patient recovered. No further information is available.
Developed hives on neck, arms, back and chest approximately 2 hours after receiving vaccine.  Did not develop respiratory issues.  Hives lasted one week.
At approximately 4:00 PM the next day pt experienced erythema, swelling at injection site. A rash appeared on both wrists and dorsal. 8PM T384
Second dose exceeding 42 days; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose exceeding 42 days) in a 77-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).    On 06-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Feb-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose exceeding 42 days). On 06-Feb-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose exceeding 42 days) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       This report refers to a case of inappropriate schedule of product administration, for mRNA-1273, lot #unknown, with no associated AEs.; Sender's Comments: This report refers to a case of inappropriate schedule of product administration, for mRNA-1273, lot #unknown, with no associated AEs.
This spontaneous report was received from a health professional refers to a patient of unknown age. The patient was vaccinated with a dose of VARIVAX (Merck) (route, dose, lot# unknown) on an unspecified date. It was reported on an unknown date the patient had a full blown rash that persisted for several weeks and was hospitalized at hospital on an unspecified date. The rash only resolved with treatment. At the time of reporting, the patient's outcome was unknown. It was unspecified whether the patient sought medical attention. Additional information has been requested.
swelling and multiple wheals on her right upper arm near the injection site; swelling and multiple wheals on her right upper arm near the injection site; This spontaneous report as received from a physician and refers to a 55-year-old female patient. The patient current condition included penicillin allergy. Concomitant therapy included flu shot (unspecified). There was no information about the patient's medical history provided.   On 08-NOV-2020, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX 23) lot # t020639, expiration date 13-MAR-2022, 1 dosage form, intramuscularly in the right deltoid muscle for pneumonia prevention. On the same date in the evening, the patient developed swelling and multiple wheals on her right upper arm near the injection site. The reporter said the wheals were 7-8 inches in diameter. One wheal developed on the top of her arm, one wheal on the side of her arm, and one 5-6 inches below the injection site. The patient said the wheal on top of her arm and the one on the side of her arm have disappeared. The only remaining wheal was the one 5-6 inches below the injection site. The patient did not receive any treatment for the wheals.The outcome of peripheral swelling and urticaria was reported as recovering.  The causality assessment between the events and the suspect therapy was not provided. combinationproductreport: Yes; brandname: PNEUMOVAX23 SYRINGE (DEVICE); commondevicename: Pneumococcal Vaccine, Polyvalent (23-valent); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: t020639; expirationdate: 13-MAR-2022; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not suggest a causal association with the device or device constituent
Information has been received from a physician concerning her daughter with a history of childhood eczema and a normal delivery 3 and 1/2 months ago who on two unspecified dates in 1998 was vaccinated with first and second doses of varicella virus vaccine live (Oka/Merck) 3 to 4 weeks apart. The patient was an adult in 1998 at the time of vaccination. Recently the patient had titers that were either very low or negative. Unspecified medical attention was sought. Lab studies were performed for varicella titer which was low or negative. No further information was provided. There was no product quality complaint involved. No further information is expected.
Long term genital skin tags have reduced in size 90% since taking vaccine and would like to share this information
Either a small cyst or swollen lymph node that last for more than three weeks, worsened after the second dose of HepB and Varicella on 1/30/2017; observing for 4 more weeks.
Pt stated that with in about a week she started having muscle weakness and that it has progressively gotten worse.  She was walking with a walker quite a bit prior to vaccination but no uses a motorized WC.   Provider requested a VAERS report to be submitted.
A report has been received from a Health Professional. The report concerning a patient born on 17-Jan-2009, Female subject, Height: 41.0 inches; Weight: 33.0 Pounds, who had been receiving Nasal FLUMIST Quadrivalent (Intranasal), 0.2 Milliliters, Once/Single administration. FLUMIST Quadrivalent (Intranasal) started on an unknown date for vaccine. The patient experienced expired FLUMIST. FLUMIST Quadrivalent (Intranasal) was continued. The outcome of the event expired FLUMIST is unknown. The report was considered to be non-serious by the company physician.
Woke up with achy upper back (~18hrs post vaccine) and low grade fever (99.3), exhausted. Proceeded to get mild chills & headache 2-3 hours later. Headache, chills, aches continued to intensify as fever continued to climb (t-max 102.1).  Took 600 mg of ibuprofen 32 hrs post vaccine. Woke up 4 hours later and headache was gone, fever broke. Continued to be chilled/achy/exhausted for up to 4 days post vaccine
Suffered  a heart attack which resulted in a fall from 3 steps to asphalt.  Concussion/ memory loss, no broken bones
pt recvd flu vax & 3 days later was hospitalized w/chest pain & was found to have pneumonia w/white blood cell count of 15,000cu/mm; pt has coronary artery disease;
Information has been received from a female consumer with no pertinent medical history or drug allergies, who on 11-OCT-2007 was vaccinated with one dose of zoster vaccine live (Oka/Merck). There was no concomitant medication. On 12-OCT-2007, the patient woke up during the night with chills, sweating and a slight headache. On 13-OCT-2007, the patient also experienced loss of appetite and no energy. No medical attention was sought. No labs or diagnostic studies were performed. On that same day the patient recovered. There was no product quality complaint. No further information is available.